Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html

Study Counts

Type Study_count
Total_Studies 131
interventional 122
Observational 8
Registry 1

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 33
Drug|Other 21
Biological|Other 9
Biological|Drug 8
Biological 6
Drug|Other|Procedure|Radiation 5
Biological|Drug|Procedure|Radiation 4
Biological|Drug|Other 3
Biological|Drug|Other|Procedure|Radiation 3
Drug|Genetic|Other 3
Drug|placebo 3
Drug|Procedure 3
Drug|Radiation 3
Drug|Other|Procedure 2
Biological|Device|Drug|Procedure|Radiation 1
Biological|Drug|Genetic|Other 1
Biological|Drug|Other|Procedure 1
Biological|Other|Procedure 1
Biological|Procedure|Radiation 1
Device|Drug 1
Dietary Supplement|Drug 1
Dietary Supplement|Other 1
Drug|Genetic|Procedure|Radiation 1
Drug|Other|Radiation 1
Drug|placebo|Procedure 1
Drug|Procedure|Radiation 1
Genetic 1
Other|Procedure 1
Other|Radiation 1
Radiation 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 96
United States|Italy 5
United States|Canada 3
United States|Germany|Italy 3
Austria 1
Austria|Belgium|France|Germany|Greece|Italy|Japan|Netherlands|Poland|Spain|Switzerland|United Kingdom 1
Austria|Germany|Israel|Italy|Switzerland|United Kingdom 1
Egypt 1
NA 1
Spain|Switzerland 1
United Kingdom 1
United States|Australia|Austria|Belgium|Brazil|France|Germany|Italy|Poland|Spain|Switzerland|United Kingdom 1
United States|Australia|Austria|Canada|Germany|Netherlands|Poland|Russian Federation|Switzerland|United Kingdom 1
United States|Australia|Austria|Canada|Germany|Poland|Russian Federation|Switzerland|United Kingdom 1
United States|Australia|Belgium|Canada|France|Italy|Spain|United Kingdom 1
United States|Australia|France|Italy|Korea, Republic of|Poland|Russian Federation|Spain|Turkey 1
United States|Belgium|France|Italy|Spain|United Kingdom 1
United States|France|Germany|Italy|Spain|United Kingdom 1
United States|Germany 1

Sites per Study

Site_count Study_Count
1 67
2 11
3 5
4 3
5 6
7 4
8 2
9 1
10 1
11 5
12 1
19 1
20 3
21 2
23 1
25 1
27 1
33 1
34 1
35 1
41 1
43 1
47 1
62 1

Phase

Phase Study_Count
Phase 2 52
Phase 1 38
Phase 1/Phase 2 13
N/A 10
Phase 3 5
Phase 4 3
Early Phase 1 1

Number of Arms

Number_of_Arms Count_of_Studies
1 86
2 23
3 4
5 1
6 1
NA 7

Enrollment Metrics by Phase

Measure Early.Phase.1 N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.3 Phase.4
Min. 33 5.00 2.00000 5.00000 4.00000 28.0 7.0
1st Qu. 33 22.25 20.00000 29.00000 29.50000 30.0 46.5
Median 33 58.50 32.00000 33.00000 49.00000 131.0 86.0
Mean 33 90.30 35.68421 40.76923 63.94118 103.6 96.0
3rd Qu. 33 75.75 52.50000 43.00000 75.50000 160.0 140.5
Max. 33 423.00 80.00000 124.00000 260.00000 169.0 195.0

Trial Group Type

group_type Group_Count
Experimental 136
Active Comparator 13
NA 7
No Intervention 3
Placebo Comparator 3

Intervention Model

intervention_model Study_Count
Single Group Assignment 91
Parallel Assignment 23
Sequential Assignment 4
NA 3
Crossover Assignment 1

Primary Purpose

primary_purpose Study_Count
Treatment 112
Supportive Care 8
Basic Science 1
Diagnostic 1

Observational Studies

Studies by Country

Country Study_Count
United States 7
United States|Argentina|Australia|Brazil|China|Japan|United Kingdom 1

Sites per Study

Site_count Study_Count
1 7
13 1

Enrollment Metrics

Measure Observational
Min 8.000
1st Qu 10.000
Median 40.000
Mean 307.625
3rd Qu 164.750
Max 2000.000

Observation Model

observational_model Study_Count
Cohort 3
NA 3
Case-Control 1
Other 1

Time Perspective

time_perspective Study_Count
Prospective 7
NA 1

Registries

Studies by Country

Country Study_Count
United States 1

Sites per Study

Site_count Study_Count
36 1

Enrollment Metrics

Measure Registries
Min 300
1st Qu 300
Median 300
Mean 300
3rd Qu 300
Max 300

Registry Model

observational_model Study_Count
Cohort 1

Time Perspective

time_perspective Study_Count
Prospective 1

Follow-up

target_duration Study_Count
2 Years 1

Overview of Studies

Interventional Trials

#If less then 500 trials

nct_id brief_title link overall_status source primary_completion_date
NCT03380026 Mechlorethamine Induced Contact Dermatitis Avoidance Study https://ClinicalTrials.gov/show/NCT03380026 Recruiting Rochester Skin Lymphoma Medical Group, PLLC 2019-12-13
NCT03357224 PARCT: Trial of Atezolizumab in Relapsed/Refractory Cutaneous T Cell Lymphoma (CTCL) https://ClinicalTrials.gov/show/NCT03357224 Recruiting European Organisation for Research and Treatment of Cancer - EORTC 2021-09-30
NCT03278782 Study of Pembrolizumab (MK-3475) in Combination With Romidepsin https://ClinicalTrials.gov/show/NCT03278782 Active, not recruiting M.D. Anderson Cancer Center 2020-11-30
NCT03063632 Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma https://ClinicalTrials.gov/show/NCT03063632 Active, not recruiting National Cancer Institute (NCI) 2021-05-01
NCT03017820 VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, or T-cell Lymphoma https://ClinicalTrials.gov/show/NCT03017820 Recruiting Mayo Clinic 2021-01-15
NCT03011814 Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma https://ClinicalTrials.gov/show/NCT03011814 Recruiting City of Hope Medical Center 2023-03-08
NCT02978625 Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers https://ClinicalTrials.gov/show/NCT02978625 Recruiting National Cancer Institute (NCI) 2021-06-01
NCT02822586 TSEB and Brentuximab for Treatment of Mycosis Fungoides & Sezary Syndrome https://ClinicalTrials.gov/show/NCT02822586 Completed Virginia Commonwealth University 2019-04-29
NCT02652715 Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT02652715 Completed Mayo Clinic 2018-12-21
NCT03398161 Ultra Low Dose Radiation Therapy in Treating Patients With Mycosis Fungoides https://ClinicalTrials.gov/show/NCT03398161 Recruiting M.D. Anderson Cancer Center 2020-09-30
NCT02542124 NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT) https://ClinicalTrials.gov/show/NCT02542124 Active, not recruiting Neumedicines Inc. 2019-02-28
NCT02520791 Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma https://ClinicalTrials.gov/show/NCT02520791 Recruiting National Cancer Institute (NCI) 2020-12-31
NCT02448381 FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides) https://ClinicalTrials.gov/show/NCT02448381 Active, not recruiting Soligenix 2019-12-31
NCT02341209 Doxycycline for the Treatment of Cutaneous T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT02341209 Recruiting Rochester General Hospital 2020-02-06
NCT02243579 Pembrolizumab in Treating Patients With Relapsed or Refractory Stage IB-IVB Mycosis Fungoides or Sezary Syndrome https://ClinicalTrials.gov/show/NCT02243579 Completed National Cancer Institute (NCI) 2018-01-04
NCT02232516 Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT02232516 Recruiting Northwestern University 2022-07-31
NCT03385226 A Trial Assessing the Effect of Pembrolizumab Combined With Radiotherapy in Patients With Relapsed, Refractory, Specified Stages of Cutaneous T-cell Lymphoma (CTCL) Mycosis Fungoides (MF)/Sezary Syndrome (SS) https://ClinicalTrials.gov/show/NCT03385226 Recruiting University College, London 2022-01-31
NCT02168140 CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT02168140 Active, not recruiting Wake Forest University Health Sciences 2019-04-18
NCT01273766 Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01273766 Completed Wake Forest University Health Sciences 2012-03-31
NCT02811783 Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL https://ClinicalTrials.gov/show/NCT02811783 Recruiting Elorac, Inc. 2022-06-30
NCT01959477 Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant https://ClinicalTrials.gov/show/NCT01959477 Completed Case Comprehensive Cancer Center 2015-01-31
NCT01839916 Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01839916 Completed University of Chicago 2018-08-31
NCT01800838 Silicon Phthalocyanine 4 and Photodynamic Therapy in Stage IA-IIA Cutaneous T-Cell Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01800838 Completed Case Comprehensive Cancer Center 2014-09-30
NCT01760655 Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01760655 Recruiting Thomas Jefferson University 2021-03-31
NCT01748721 MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma https://ClinicalTrials.gov/show/NCT01748721 Completed Morphotek 2015-05-31
NCT01686594 PUVA Maintenance Therapy in Mycosis Fungoides https://ClinicalTrials.gov/show/NCT01686594 Completed Medical University of Graz 2018-07-02
NCT01678443 Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies https://ClinicalTrials.gov/show/NCT01678443 Active, not recruiting Fred Hutchinson Cancer Research Center 2011-04-11
NCT01658319 Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01658319 Completed Case Comprehensive Cancer Center 2015-02-28
NCT01590732 Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT01590732 Completed M.D. Anderson Cancer Center 2018-05-02
NCT01588015 Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT01588015 Active, not recruiting City of Hope Medical Center 2021-11-30
NCT01578499 A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician’s Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study) https://ClinicalTrials.gov/show/NCT01578499 Completed Takeda 2016-05-31
NCT01567709 Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT01567709 Completed National Cancer Institute (NCI) 2018-03-29
NCT01529827 Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01529827 Completed Roswell Park Cancer Institute 2015-05-28
NCT01523223 Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies https://ClinicalTrials.gov/show/NCT01523223 Completed Stanford University 2016-09-30
NCT01484015 Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia https://ClinicalTrials.gov/show/NCT01484015 Completed Wake Forest University Health Sciences 2012-06-30
NCT01427881 Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies https://ClinicalTrials.gov/show/NCT01427881 Completed Fred Hutchinson Cancer Research Center 2014-06-30
NCT01396070 Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level https://ClinicalTrials.gov/show/NCT01396070 Completed Stanford University 2015-04-30
NCT01384513 A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies https://ClinicalTrials.gov/show/NCT01384513 Recruiting Thomas Jefferson University 2020-12-31
NCT01352520 SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP) https://ClinicalTrials.gov/show/NCT01352520 Active, not recruiting M.D. Anderson Cancer Center 2021-01-31
NCT01326702 Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors https://ClinicalTrials.gov/show/NCT01326702 Completed National Cancer Institute (NCI) 2015-04-30
NCT04256018 Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome https://ClinicalTrials.gov/show/NCT04256018 Recruiting Stanford University 2022-02-28
NCT04185220 Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome https://ClinicalTrials.gov/show/NCT04185220 Recruiting National Institutes of Health Clinical Center (CC) 2023-03-01
NCT04101331 Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides https://ClinicalTrials.gov/show/NCT04101331 Recruiting Affimed GmbH 2022-04-30
NCT03905135 Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies https://ClinicalTrials.gov/show/NCT03905135 Recruiting National Institutes of Health Clinical Center (CC) 2022-03-01
NCT03902184 IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma https://ClinicalTrials.gov/show/NCT03902184 Recruiting Innate Pharma 2022-03-01
NCT03837457 PRISM: Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Mycosis Fungoides Who Have Completed the SOLAR Study https://ClinicalTrials.gov/show/NCT03837457 Enrolling by invitation miRagen Therapeutics, Inc. 2021-12-31
NCT03713320 SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis Fungoides https://ClinicalTrials.gov/show/NCT03713320 Active, not recruiting miRagen Therapeutics, Inc. 2021-04-30
NCT03695471 Pembrolizumab in Treating Patients With Stage IB-IV Mycosis Fungoides https://ClinicalTrials.gov/show/NCT03695471 Recruiting Mayo Clinic 2022-10-11
NCT03602157 Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL https://ClinicalTrials.gov/show/NCT03602157 Recruiting UNC Lineberger Comprehensive Cancer Center 2026-09-30
NCT03598998 Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas https://ClinicalTrials.gov/show/NCT03598998 Recruiting City of Hope Medical Center 2021-04-27
NCT03587844 Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients https://ClinicalTrials.gov/show/NCT03587844 Recruiting Memorial Sloan Kettering Cancer Center 2021-07-31
NCT03454945 Efficacy of Doxycycline in the Treatment of Early Stages of Mycosis Fungoides https://ClinicalTrials.gov/show/NCT03454945 Recruiting Cairo University 2019-04-01
NCT01261247 Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01261247 Active, not recruiting Mayo Clinic 2016-05-09
NCT01254578 Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers https://ClinicalTrials.gov/show/NCT01254578 Completed National Cancer Institute (NCI) 2012-11-09
NCT01233921 Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer https://ClinicalTrials.gov/show/NCT01233921 Completed Fred Hutchinson Cancer Research Center 2012-07-31
NCT01231919 MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia https://ClinicalTrials.gov/show/NCT01231919 Completed National Cancer Institute (NCI) 2013-04-30
NCT01134341 Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma https://ClinicalTrials.gov/show/NCT01134341 Completed Acrotech Biopharma LLC 2015-08-31
NCT01129193 AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma https://ClinicalTrials.gov/show/NCT01129193 Completed Ohio State University Comprehensive Cancer Center 2017-01-07
NCT01129180 Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT01129180 Completed Ohio State University Comprehensive Cancer Center 2012-05-31
NCT01110135 Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma https://ClinicalTrials.gov/show/NCT01110135 Completed University of Washington 2013-11-30
NCT01158274 RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors https://ClinicalTrials.gov/show/NCT01158274 Completed National Cancer Institute (NCI) 2012-08-31
NCT01075321 Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01075321 Active, not recruiting Mayo Clinic 2015-02-28
NCT01073267 Study of Total Skin Electron Beam Therapy (TSEBT) in Stage IB-IIIA Mycosis Fungoides https://ClinicalTrials.gov/show/NCT01073267 Completed M.D. Anderson Cancer Center 2014-12-31
NCT01053494 Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer https://ClinicalTrials.gov/show/NCT01053494 Completed Wake Forest University Health Sciences 2012-02-29
NCT00961220 O6-Benzylguanine and Topical Carmustine in Treating Patients With Early-Stage IA-IIA Cutaneous T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT00961220 Completed National Cancer Institute (NCI) 2012-04-08
NCT00918333 Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT00918333 Completed Mayo Clinic 2015-12-01
NCT00890747 Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy https://ClinicalTrials.gov/show/NCT00890747 Completed National Cancer Institute (NCI) 2011-05-31
NCT00856388 Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders https://ClinicalTrials.gov/show/NCT00856388 Completed Roswell Park Cancer Institute 2012-08-09
NCT01258998 Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma https://ClinicalTrials.gov/show/NCT01258998 Completed National Cancer Institute (NCI) 2014-07-31
NCT01805037 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas https://ClinicalTrials.gov/show/NCT01805037 Active, not recruiting Northwestern University 2021-01-31
NCT02953301 Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS) https://ClinicalTrials.gov/show/NCT02953301 Recruiting 4SC AG 2022-01-31
NCT03281811 Photodynamic Therapy in Treating Patients With Refractory Mycosis Fungoides https://ClinicalTrials.gov/show/NCT03281811 Active, not recruiting Mayo Clinic 2020-02-25
NCT02580552 Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL https://ClinicalTrials.gov/show/NCT02580552 Active, not recruiting miRagen Therapeutics, Inc. 2020-12-31
NCT01177371 High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01177371 Completed Case Comprehensive Cancer Center 2000-02-29
NCT00769288 FAU in Treating Patients With Advanced Solid Tumors or Lymphoma https://ClinicalTrials.gov/show/NCT00769288 Completed National Cancer Institute (NCI) 2013-12-31
NCT00611208 A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL) https://ClinicalTrials.gov/show/NCT00611208 Completed Angimmune LLC 2015-02-28
NCT00608361 Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery https://ClinicalTrials.gov/show/NCT00608361 Completed National Cancer Institute (NCI) 2014-08-31
NCT00601718 Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT00601718 Completed University of Washington 2010-06-30
NCT00535470 An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides https://ClinicalTrials.gov/show/NCT00535470 Completed Yaupon Therapeutics 2011-03-31
NCT00499811 Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction https://ClinicalTrials.gov/show/NCT00499811 Completed National Cancer Institute (NCI) 2011-08-31
NCT00489203 Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer https://ClinicalTrials.gov/show/NCT00489203 Completed Fred Hutchinson Cancer Research Center 2010-11-30
NCT00466921 Lenalidomide in Treating Patients With Relapsed Mycosis Fungoides/Sezary Syndrome https://ClinicalTrials.gov/show/NCT00466921 Active, not recruiting Northwestern University 2020-02-29
NCT00458731 Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma https://ClinicalTrials.gov/show/NCT00458731 Completed National Cancer Institute (NCI) 2013-12-31
NCT01093586 Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01093586 Completed Case Comprehensive Cancer Center 2015-12-31
NCT00408681 Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT00408681 Completed Fred Hutchinson Cancer Research Center 2010-11-30
NCT00348985 PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas https://ClinicalTrials.gov/show/NCT00348985 Completed National Cancer Institute (NCI) 2010-01-31
NCT00293345 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma https://ClinicalTrials.gov/show/NCT00293345 Completed National Cancer Institute (NCI) 2012-10-31
NCT00221039 Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A https://ClinicalTrials.gov/show/NCT00221039 Completed M.D. Anderson Cancer Center 2011-04-05
NCT00185965 CPG 7909 + Local Radiotherapy in Recurrent Low-Grade Lymphomas https://ClinicalTrials.gov/show/NCT00185965 Completed Stanford University 2010-03-31
NCT00178841 Combination Drug Study of Bexarotene and Rosiglitazone to Treat CTCL https://ClinicalTrials.gov/show/NCT00178841 Completed Vanderbilt University 2007-03-31
NCT00168064 Safety and Efficacy of Nitrogen Mustard in Treatment of Mycosis Fungoides https://ClinicalTrials.gov/show/NCT00168064 Completed Yaupon Therapeutics 2010-08-31
NCT00118352 Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer https://ClinicalTrials.gov/show/NCT00118352 Completed Fred Hutchinson Cancer Research Center 2010-07-31
NCT00112593 Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer https://ClinicalTrials.gov/show/NCT00112593 Completed Fred Hutchinson Cancer Research Center 2014-11-30
NCT00103246 Photodynamic Therapy Using Silicon Phthalocyanine 4 in Treating Patients With Actinic Keratosis, Bowen’s Disease, Skin Cancer, or Stage I or Stage II Mycosis Fungoides https://ClinicalTrials.gov/show/NCT00103246 Completed Case Comprehensive Cancer Center 2008-12-31
NCT00098891 MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas https://ClinicalTrials.gov/show/NCT00098891 Completed National Cancer Institute (NCI) 2008-03-31
NCT00091559 Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001) https://ClinicalTrials.gov/show/NCT00091559 Completed Merck Sharp & Dohme Corp. 2005-11-23
NCT00002479 Tretinoin in Treating Patients With Mycosis Fungoides or Sezary Syndrome https://ClinicalTrials.gov/show/NCT00002479 Completed Northwestern University 2002-08-31
NCT00089271 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas https://ClinicalTrials.gov/show/NCT00089271 Completed National Cancer Institute (NCI) 2010-06-30
NCT00089011 Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer https://ClinicalTrials.gov/show/NCT00089011 Completed Fred Hutchinson Cancer Research Center 2014-03-31
NCT00003196 Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma https://ClinicalTrials.gov/show/NCT00003196 Completed Fred Hutchinson Cancer Research Center 2002-04-30
NCT00006251 Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer https://ClinicalTrials.gov/show/NCT00006251 Completed Fred Hutchinson Cancer Research Center 2005-09-30
NCT00005080 506U78 in Treating Patients With Lymphoma https://ClinicalTrials.gov/show/NCT00005080 Completed National Cancer Institute (NCI) 2006-01-31
NCT00005799 Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer https://ClinicalTrials.gov/show/NCT00005799 Completed Fred Hutchinson Cancer Research Center 2002-07-31
NCT00078858 Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT00078858 Completed Fred Hutchinson Cancer Research Center 2006-01-31
NCT00077155 Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma https://ClinicalTrials.gov/show/NCT00077155 Completed National Cancer Institute (NCI) 2010-06-30
NCT00074087 Liposomal Doxorubicin in Treating Patients With Stage IIB, Stage IVA, or Stage IVB Recurrent or Refractory Mycosis Fungoides https://ClinicalTrials.gov/show/NCT00074087 Completed European Organisation for Research and Treatment of Cancer - EORTC 2009-07-31
NCT00072514 Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies https://ClinicalTrials.gov/show/NCT00072514 Completed Fred Hutchinson Cancer Research Center 2008-07-31
NCT00003210 Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin’s Lymphoma or Hodgkin’s Disease https://ClinicalTrials.gov/show/NCT00003210 Completed National Cancer Institute (NCI) 2003-11-30
NCT00066664 Serum Protein Patterns in Participants With Mycosis Fungoides/Cutaneous T-Cell Lymphoma, Psoriasis, or Normal Skin https://ClinicalTrials.gov/show/NCT00066664 Completed National Institutes of Health Clinical Center (CC) 2007-12-31
NCT00057967 Alemtuzumab in Treating Patients With Relapsed or Refractory Advanced Mycosis Fungoides or Sézary Syndrome https://ClinicalTrials.gov/show/NCT00057967 Completed Northwestern University 2007-06-26
NCT00049504 Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer https://ClinicalTrials.gov/show/NCT00049504 Completed Fred Hutchinson Cancer Research Center 2011-03-31
NCT00047060 Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome https://ClinicalTrials.gov/show/NCT00047060 Completed National Institutes of Health Clinical Center (CC) 2019-01-24
NCT00040846 Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies https://ClinicalTrials.gov/show/NCT00040846 Completed Fred Hutchinson Cancer Research Center 2009-12-31
NCT00795769 Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant https://ClinicalTrials.gov/show/NCT00795769 Completed Fred Hutchinson Cancer Research Center 2009-06-09
NCT00025415 Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction https://ClinicalTrials.gov/show/NCT00025415 Completed National Cancer Institute (NCI) 2005-01-31
NCT00014235 Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00014235 Completed Fred Hutchinson Cancer Research Center 2005-02-28
NCT00004241 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma https://ClinicalTrials.gov/show/NCT00004241 Completed National Cancer Institute (NCI) 2006-05-31
NCT00003970 Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma https://ClinicalTrials.gov/show/NCT00003970 Completed National Cancer Institute (NCI) 2003-10-31
NCT00002687 Interleukin-2 in Treating Patients With Mycosis Fungoides https://ClinicalTrials.gov/show/NCT00002687 Completed University of Washington 2003-07-31
NCT00051012 Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients https://ClinicalTrials.gov/show/NCT00051012 Completed Eisai Inc. 2006-10-31
NCT00050999 Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients https://ClinicalTrials.gov/show/NCT00050999 Completed Eisai Inc. 2006-09-30
NCT00038376 Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies https://ClinicalTrials.gov/show/NCT00038376 Completed M.D. Anderson Cancer Center 2005-06-30

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT02848274 ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome https://ClinicalTrials.gov/show/NCT02848274 Recruiting Stanford University 2022-03-31
NCT02702310 Low-Dose Total Skin Electron Therapy in Treating Patients With Refractory or Relapsed Stage IB-IIIA Mycosis Fungoides https://ClinicalTrials.gov/show/NCT02702310 Recruiting Vanderbilt-Ingram Cancer Center 2020-12-31
NCT03789864 Biodynamic Imaging Utility in Predicting Response to Gemcitabine Chemotherapy in Mycosis Fungoides https://ClinicalTrials.gov/show/NCT03789864 Recruiting Indiana University 2021-05-01
NCT01199562 Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT01199562 Completed City of Hope Medical Center 2013-12-31
NCT00368784 T Cell Repertoire Analysis of Immune Mediated Skin Diseases https://ClinicalTrials.gov/show/NCT00368784 Recruiting University of California, Davis 2021-10-31
NCT00254332 Effect of Denileukin Diftitox on Immune System in CTCL Patients https://ClinicalTrials.gov/show/NCT00254332 Completed FDA Office of Orphan Products Development NA
NCT00177268 Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research https://ClinicalTrials.gov/show/NCT00177268 Recruiting University of Pittsburgh 2027-01-31
NCT00177190 In Vitro Evaluation of Immune Responses in Cutaneous T-Cell Lymphoma (CTCL) https://ClinicalTrials.gov/show/NCT00177190 Completed University of Pittsburgh 2005-01-31

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT02296164 Clinical Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell Lymphoma https://ClinicalTrials.gov/show/NCT02296164 Completed Helsinn Therapeutics (U.S.), Inc 2018-10-17